Apellis Valuation Undervalues Empaveli Opportunity in Rare Kidney Disease, BofA Says

MT Newswires Live01-22

Apellis Pharmaceuticals' (APLS) current valuation does not fully reflect the commercial opportunity for Empaveli in rare kidney diseases such as C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN), BofA Securities said in a note Wednesday.

The analysts said in the research note that Empaveli has shown strong early uptake in the US since approval in late July, with about 5% penetration of the patient population and no full denials reported to date.

They noted that management attributes the momentum to a broader label and stronger efficacy versus competitors, while recent European approval via partner Sobi supports a longer-term global opportunity.

BofA sees peak US sales reaching about $508 million in 2033.

The company also expects more modest growth in its geographic atrophy drug Syfovre in 2026, following funding challenges in 2025, but believes a planned prefilled syringe version could help re-accelerate uptake, the analysts said, adding that they project the impact of the prefilled syringe to be felt in 2027.

BofA upgraded Apellis Pharmaceuticals to buy from neutral and set $28 as the price objective.

Shares of Apellis Pharmaceuticals were up more than 3% in recent trading.

Price: 21.11, Change: +0.64, Percent Change: +3.10

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605489128?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 00:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605489128","market":"sh","top_or_hot":-1,"title":"Apellis Valuation Undervalues Empaveli Opportunity in Rare Kidney Disease, BofA Says","media":"MT Newswires Live","content":"<html><body><p> Apellis Pharmaceuticals' (APLS) current valuation does not fully reflect the commercial opportunity for Empaveli in rare kidney diseases such as C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN), BofA Securities said in a note Wednesday.</p><p>The analysts said in the research note that Empaveli has shown strong early uptake in the US since approval in late July, with about 5% penetration of the patient population and no full denials reported to date.</p><p>They noted that management attributes the momentum to a broader label and stronger efficacy versus competitors, while recent European approval via partner Sobi supports a longer-term global opportunity.</p><p>BofA sees peak US sales reaching about $508 million in 2033.</p><p>The company also expects more modest growth in its geographic atrophy drug Syfovre in 2026, following funding challenges in 2025, but believes a planned prefilled syringe version could help re-accelerate uptake, the analysts said, adding that they project the impact of the prefilled syringe to be felt in 2027.</p><p>BofA upgraded Apellis Pharmaceuticals to buy from neutral and set $28 as the price objective.</p><p>Shares of Apellis Pharmaceuticals were up more than 3% in recent trading.</p><p>Price: 21.11, Change: +0.64, Percent Change: +3.10</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apellis Valuation Undervalues Empaveli Opportunity in Rare Kidney Disease, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApellis Valuation Undervalues Empaveli Opportunity in Rare Kidney Disease, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-22 00:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Apellis Pharmaceuticals' (APLS) current valuation does not fully reflect the commercial opportunity for Empaveli in rare kidney diseases such as C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN), BofA Securities said in a note Wednesday.</p><p>The analysts said in the research note that Empaveli has shown strong early uptake in the US since approval in late July, with about 5% penetration of the patient population and no full denials reported to date.</p><p>They noted that management attributes the momentum to a broader label and stronger efficacy versus competitors, while recent European approval via partner Sobi supports a longer-term global opportunity.</p><p>BofA sees peak US sales reaching about $508 million in 2033.</p><p>The company also expects more modest growth in its geographic atrophy drug Syfovre in 2026, following funding challenges in 2025, but believes a planned prefilled syringe version could help re-accelerate uptake, the analysts said, adding that they project the impact of the prefilled syringe to be felt in 2027.</p><p>BofA upgraded Apellis Pharmaceuticals to buy from neutral and set $28 as the price objective.</p><p>Shares of Apellis Pharmaceuticals were up more than 3% in recent trading.</p><p>Price: 21.11, Change: +0.64, Percent Change: +3.10</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLS","symbol_name":"Apellis Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2605489128","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605489128","pubTimestamp":1769012356,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Apellis Pharmaceuticals' (APLS) current valuation does not fully reflect the commercial opportunity for Empaveli in rare kidney diseases such as C3 glomerulopathy (C3G) or immune-complex membranoproli","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLS":"Apellis Pharmaceuticals Inc.","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4139":"生物科技","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股"},"translate_title":"美国银行表示，Apellis估值低估了Empaveli在罕见肾病领域的机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":1},"content_text":"Apellis Pharmaceuticals' (APLS) current valuation does not fully reflect the commercial opportunity for Empaveli in rare kidney diseases such as C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN), BofA Securities said in a note Wednesday.The analysts said in the research note that Empaveli has shown strong early uptake in the US since approval in late July, with about 5% penetration of the patient population and no full denials reported to date.They noted that management attributes the momentum to a broader label and stronger efficacy versus competitors, while recent European approval via partner Sobi supports a longer-term global opportunity.BofA sees peak US sales reaching about $508 million in 2033.The company also expects more modest growth in its geographic atrophy drug Syfovre in 2026, following funding challenges in 2025, but believes a planned prefilled syringe version could help re-accelerate uptake, the analysts said, adding that they project the impact of the prefilled syringe to be felt in 2027.BofA upgraded Apellis Pharmaceuticals to buy from neutral and set $28 as the price objective.Shares of Apellis Pharmaceuticals were up more than 3% in recent trading.Price: 21.11, Change: +0.64, Percent Change: +3.10","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605489128","isCrawlerRequest":true}